Findings

What do systematic reviews say?

100 questions · 100 findings · 15 reviews · Vascular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 32 · 32%GRADE not reported 4 · 4%Very low 13 · 13%Low 35 · 35%Moderate 15 · 15%High 1 · 1%

[Radial] Oblique‐axis in‐plane B‐mode ultrasound vs long‐axis in‐plane B‐mode ultrasound

Pseudoaneurysm · adults requiring radial artery catheterisation

The review found no eligible studies for this question.

1 finding from 1 review

Ultrasound guidance for arterial (other than femoral) catheterisation in adults 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

[Radial] Oblique‐axis in‐plane B‐mode ultrasound vs long‐axis in‐plane B‐mode ultrasound

Overall success rate · adults requiring radial artery catheterisation

[Radial] Oblique‐axis in‐plane B‐mode ultrasound may leads to higher overall success rate compared with long‐axis in‐plane B‐mode ultrasound (low certainty).

1 finding from 1 review

Ultrasound guidance for arterial (other than femoral) catheterisation in adults 2021 · Cochrane Headline outcomes only
RR 1.27 [1.05, 1.53]
2 studies · 215 participants
Low

[Radial] Oblique‐axis in‐plane B‐mode ultrasound vs long‐axis in‐plane B‐mode ultrasound

Time needed for a successful procedure · adults requiring radial artery catheterisation

1 finding from 1 review

Ultrasound guidance for arterial (other than femoral) catheterisation in adults 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 275 participants
Very low

[Radial] Oblique‐axis in‐plane B‐mode ultrasound vs long‐axis in‐plane B‐mode ultrasound

Major haematoma · adults requiring radial artery catheterisation

It is very uncertain whether [Radial] Oblique‐axis in‐plane B‐mode ultrasound changes major haematoma compared with long‐axis in‐plane B‐mode ultrasound (very low certainty).

1 finding from 1 review

Ultrasound guidance for arterial (other than femoral) catheterisation in adults 2021 · Cochrane Headline outcomes only
RR 0.68 [0.32, 1.47]
2 studies · 215 participants
Very low

[Radial] Oblique‐axis in‐plane B‐mode ultrasound vs long‐axis in‐plane B‐mode ultrasound

Adverse events (pain) · adults requiring radial artery catheterisation

The review found no eligible studies for this question.

1 finding from 1 review

Ultrasound guidance for arterial (other than femoral) catheterisation in adults 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

[Radial] Oblique‐axis in‐plane B‐mode ultrasound vs long‐axis in‐plane B‐mode ultrasound

Quality of life · adults requiring radial artery catheterisation

The review found no eligible studies for this question.

1 finding from 1 review

Ultrasound guidance for arterial (other than femoral) catheterisation in adults 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Avoralstat vs placebo

Risk of HAE attacks (during · children or adults with Types I or II HAE

Avoralstat showed no clear difference in risk of HAE attacks (during compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 0.99 [0.92, 1.06]
1 study · 110 participants
Moderate

Berotralstat vs placebo or active control

Mortality (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Berotralstat vs placebo or active control

Serious adverse events (during · children or adults with Types I or II HAE

Berotralstat showed no clear difference in serious adverse events (during compared with placebo or active control (low certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 0.77 [0.02, 24.03]
3 studies · 128 participants
Low

Berotralstat vs placebo or active control

Quality of lifeAngioedema Quality of Life scale (lower score is better)(during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 130 participants
Moderate

Berotralstat vs placebo or active control

Disability standardised mean difference (lower is better) (during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 50 participants
Low

Berotralstat vs placebo or active control

Adverse events(during · children or adults with Types I or II HAE

Berotralstat showed no clear difference in adverse events(during compared with placebo or active control (moderate certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 1.03 [0.88, 1.22]
3 studies · 128 participants
Moderate

C1 esterase inhibitor vs placebo or active control

Risk of HAE attacks (during · children or adults with Types I or II HAE

C1 esterase inhibitor may leads to lower risk of HAE attacks (during compared with placebo or active control (low certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 0.29 [0.16, 0.5]
1 study · 43 participants
Low

C1 esterase inhibitor vs placebo or active control

Change in number of HAE attacks (per week) · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
Low

C1 esterase inhibitor vs placebo or active control

Mortality (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

C1 esterase inhibitor vs placebo or active control

Serious adverse events (during · children or adults with Types I or II HAE

It is very uncertain whether C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 0.34 [0.01, 8.14]
1 study · 44 participants
Very low

C1 esterase inhibitor vs placebo or active control

Improvement in quality of life: the difference in quality of life scores for participants surveyed before and after treatment · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 36 participants
Low

Avoralstat vs placebo

Change in number of HAE attacks (per week) · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 134 participants
Low

C1 esterase inhibitor vs placebo or active control

Disability (any validated scale) (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

C1 esterase inhibitor vs placebo or active control

Adverse events (during · children or adults with Types I or II HAE

C1 esterase inhibitor showed no clear difference in adverse events (during compared with placebo or active control (moderate certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 1.03 [0.84, 1.27]
1 study · 44 participants
Moderate